Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2013 Giugno;55(2) > Panminerva Medica 2013 Giugno;55(2):109-20

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

  CUTTING EDGE RESPIRATORY MEDICINE 2013


Panminerva Medica 2013 Giugno;55(2):109-20

lingua: Inglese

An update on idiopathic pulmonary fibrosis

Margaritopoulos G. A., Giannarakis I., Siafakas N. M., Antoniou K. M.

Interstitial Lung Disease Unit, University Hospital of Heraklion, Crete, Greece


PDF  


Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease with a median survival of 3-5 years. Despite recent advances the pathophysiology of the disease remains not fully understood. However, injury of type II alveolar epithelial cells is considered the key event for the initiation of the development of fibrosis. An accurate diagnosis is imperative because commencing treatment at an early stage may reduce disease progression. In this regard, the multidisciplinary disease meeting between pulmonologists, radiologists and pathologists has definitely improved the diagnostic confidence. Importantly, a milestone has been recently reached as the first IPF-specific drug namely pirfenidone has been licensed in Europe, Japan and Asia.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

gmargaritop@yahoo.gr